AstraZeneca: Diabetes Mellitus trials

The registry lists 122 Diabetes Mellitus studies with AstraZeneca as lead sponsor. 0 are open to participants now and 58 have results posted.

Phase 1 22Phase 2 16Phase 3 49Phase 4 6No phase 31(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseTerminatedNCT04492722Phase 2Results posted
• A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03745937Phase 2Results posted
• Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 DiabetesCompletedNCT03645421Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 YearsCompletedNCT02725593Phase 3Results posted
• A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT02548585Phase 1/2Results posted
• Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes MellitusCompletedNCT02426541Phase 4Results posted
• A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedNCT02419612Phase 3Results posted
• Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching PlaceboCompletedNCT02229396Phase 3Results posted
• Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes MellitusCompletedNCT02229383Phase 3Results posted
• Phase III Insulin Add-On Asia Regional Program - STCompletedNCT02096705Phase 3Results posted
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes MellitusCompletedNCT01991795Phase 3Results posted
• Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes MellitusCompletedNCT01652729Phase 3Results posted
• Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and SulfonylureaCompletedNCT01392677Phase 3Results posted
• A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy SubjectsCompletedNCT01297062Phase 1Results posted
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive MedicationCompletedNCT01195662Phase 3Results posted
• Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XRCompletedNCT01192152Phase 1Results posted
• Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)CompletedNCT01192139Phase 1Results posted
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerCompletedNCT01137474Phase 3Results posted
• Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 DiabetesCompletedNCT01060059Results posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular DiseaseCompletedNCT01042977Phase 3Results posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and HypertensionCompletedNCT01031680Phase 3Results posted
• Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01029886Phase 3Results posted
• Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 DiabetesCompletedNCT01003184Phase 3Results posted
• A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesCompletedNCT00960661Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes MellitusCompletedNCT00935532Phase 3Results posted
• A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian SubjectsCompletedNCT00917267Phase 3Results posted
• A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly SuspensionCompletedNCT00894322Phase 1/2Results posted
• A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)CompletedNCT00877890Phase 3Results posted
• A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminCompletedNCT00870194Phase 4Results posted
• Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 DiabetesCompletedNCT00859898Phase 3Results posted
• Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes MellitusCompletedNCT00765817Phase 3Results posted
• A Diabetes Study to Treat A Population Previously Not at TargetCompletedNCT00747149Phase 4Results posted
• Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 DiabetesCompletedNCT00736879Phase 3Results posted
• Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneCompletedNCT00729326Phase 4Results posted
• Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With MetforminTerminatedNCT00701935Phase 2Results posted
• Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 DiabetesCompletedNCT00658021Phase 3Results posted
• Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)CompletedNCT00641056Phase 3Results posted
• A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)CompletedNCT00637273Phase 3Results posted
• CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE TherapyCompletedNCT00635492Results posted
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and MetforminCompletedNCT00603239Phase 3Results posted
• Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)CompletedNCT00577824Phase 3Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneCompletedNCT00528879Phase 3Results posted
• A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsCompletedNCT00500370Phase 2Results posted
• Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 DiabetesCompletedNCT00434954Phase 3Results posted
• Effect on Weight Loss of Exenatide Versus PlaceboCompletedNCT00375492Phase 3Results posted
• A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes PatientsCompletedNCT00360334Phase 3Results posted
• Exenatide Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT00359762Phase 3Results posted
• A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00327015Phase 3Results posted
• Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00316082Phase 3Results posted
• A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With SulfonylureasCompletedNCT00313313Phase 3Results posted
• Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)CompletedNCT00308139Phase 3Results posted
• Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal DiseaseCompletedNCT00296400Phase 2Results posted
• Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal DiseaseCompletedNCT00296374Phase 2Results posted
• An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 DiabetesCompletedNCT00229658Results posted
• An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00135330Phase 3Results posted
• Effects of Exenatide and Insulin Glargine in Subjects With Type 2 DiabetesCompletedNCT00097500Phase 3Results posted
• Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminCompletedNCT00082407Phase 3Results posted
• Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and MetforminCompletedNCT00082381Phase 3Results posted
• A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes MellitusSuspendedNCT07433062Phase 1
• Chinese Multiple Dose Escalation (MDE) High Dose StudyCompletedNCT05437848Phase 1
• A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsCompletedNCT05294458Phase 1
• Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusCompletedNCT04208620Phase 1
• Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From TurkeyCompletedNCT03407196
• Indian Phenotype RegistryCompletedNCT03363594
• A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DMCompletedNCT03090464
• Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus PatientsCompletedNCT02588859
• Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in SingaporeCompletedNCT02578563
• A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 DiabetesCompletedNCT02524782Phase 1
• A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy VolunteersCompletedNCT02394314Phase 1
• An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes PatientsCompletedNCT02208921
• Forxiga Tablets Specific Clinical Experience Investigation for Long-term UseCompletedNCT02200666
• Forxiga Tablets Specific Clinical Experience Investigation for ElderlyCompletedNCT02200627
• Specific Clinical Experience Investigation for Long-term Use of Bydureon.CompletedNCT01940770
• An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes MellitusCompletedNCT01876849Phase 3
• Bioequivalence StudyCompletedNCT01874080Phase 1
• Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)CompletedNCT01817569
• Centralised Pan-Algerian Survey on the Undertreatment of HypercholesterolemiaCompletedNCT01768403
• Better Diabetes Control, Quality - Educate to Achieve Compliance.CompletedNCT01728714
• Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)CompletedNCT01284608
• Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With DiabetesCompletedNCT01264263
• Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.TerminatedNCT01244646
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM PatientsCompletedNCT01221545Phase 1
• A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary CareCompletedNCT01121315
• Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus PatientsCompletedNCT01103622Phase 1
• Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT01103609Phase 1
• A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood GlucoseCompletedNCT01072578Phase 1
• To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus PatientsCompletedNCT01069926Phase 1
• Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European SurveyCompletedNCT00916513
• European Study of Cardiovascular RiskCompletedNCT00882336
• Management of Diabetes Mellitus Patients With RetinopathyCompletedNCT00828425
• Survey on the Treatment of Hypertension in Patients With Type 2 DiabetesCompletedNCT00803660
• Renal Mechanism of Action/Splay vs. TmGTerminatedNCT00726505Phase 1
• OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.CompletedNCT00681850
• Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)CompletedNCT00660764
• Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino PatientsCompletedNCT00622323
• A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 DiabetesCompletedNCT00612794Phase 1
• Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)CompletedNCT00574782
• Drug Interaction With MetforminCompletedNCT00546741Phase 1
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536965
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536796